

Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-57. (Canceled).

58. (Previously presented) A method for treating non-prostate cancer in a subject comprising:

providing an antibody or antigen binding portion thereof which binds to the extracellular domain of prostate specific membrane antigen; and

administering the antibody or antigen binding portion thereof to a subject in need of treatment under conditions effective to treat non-prostate cancer.

59. (Currently amended) [[A]] The method according to claim 58, wherein the antibody or antigen binding portion thereof binds to vascular endothelial cells proximate to or within the non-prostate cancerous cells.

60. (Currently amended) [[A]] The method according to claim 58, wherein the non-prostate cancer is selected from the group consisting of renal cancer, urothelial cancer, colon cancer, rectal cancer, lung cancer, breast cancer, and metastatic adenocarcinoma [[of]] to the liver.

61. (Currently amended) [[A]] The method according to claim 58, wherein the administering is carried out parenterally.

62. (Currently amended) [[A]] The method according to claim [[61]] 58, wherein the administering is carried out intravenously.

63. (Currently amended) [[A]] The method according to claim 58, wherein the administering is carried out by intracavitary instillation.

64. (Currently amended) [[A]] The method according to claim 58, wherein the administering is carried out rectally.

65. (Currently amended) [[A]] The method according to claim 58, wherein the administering is carried out intramuscularly.

66. (Currently amended) [[A]] The method according to claim 58, wherein the antibody or antigen binding portion thereof binds live cells.

67. (Currently amended) [[A]] The method according to claim 58, wherein the antibody is selected from the group consisting of a monoclonal antibody and a polyclonal antibody.

68. (Currently amended) [[A]] The method according to claim 67, wherein the antibody is a monoclonal antibody selected from the group consisting of an E99, a J415, a J533, and a J591 monoclonal antibody.

69. (Currently amended) [[A]] The method according to claim 67, wherein the antibody is a monoclonal antibody produced by a hybridoma having an ATCC Accession Number selected from the group consisting of HB-12101, HB-12109, HB-12127, and HB-12126.

70.-71. (Canceled)

72. (Currently amended) [[A]] The method according to claim 58, wherein the antibody or antigen binding portion thereof competes for binding to prostate specific membrane antigen (PSMA) with a monoclonal antibody selected from the group consisting of an E99, a J415, a J533 and a J591 monoclonal antibody.

73. (Currently amended) [[A]] The method according to claim 72, wherein the antibody or antigen binding portion thereof competes for binding to prostate specific membrane antigen (PSMA) with a J591 monoclonal antibody.

74-83. (Canceled).

84. (Currently amended) [[A]] The method according to claim 58[[, 70]] or 72, wherein the antibody is a monoclonal antibody or the antigen binding portion thereof is derived from a monoclonal antibody.

85. (Currently amended) [[A]] The method according to claim 58[[, 70]] or 72, wherein the antibody or antigen binding portion thereof is internalized with the prostate specific membrane antigen.

86. (Currently amended) [[A]] The method according to claim 58[[, 70]] or 72, wherein the ~~antibody or antigen binding portion thereof~~ is selected from the group consisting of a Fab fragment, a [[F(ab')₂]] F(ab')₂ fragment, and a Fv fragment.

87. (Currently amended) [[A]] The method according to claim 58[[, 70]] or 72, wherein the antibody or antigen binding portion thereof ~~further~~ comprises a cytotoxic drug.

88. (Currently amended) [[A]] The method according to claim 87, wherein the cytotoxic drug is selected from the group consisting of a therapeutic drug, a compound emitting radiation,

a molecule ~~molecules~~ of plant, fungal, or bacterial origin, a biological protein ~~proteins~~, and a mixture ~~mixtures~~ thereof.

89. (Currently amended) [[A]] The method according to claim 87, wherein the cytotoxic drug is a compound emitting radiation.

90. (Currently amended) [[A]] The method according to claim 89, wherein the compound emitting radiation is an alpha-emitter.

91. (Currently amended) [[A]] The method according to claim 90, wherein the alpha-emitter is selected from the group consisting of ^{212}Bi , ^{213}Bi , and ^{211}At .

92. (Currently amended) [[A]] The method according to claim 89, wherein the compound emitting radiation is a beta-emitter.

93. (Currently amended) [[A]] The method according to claim 92, wherein the beta-emitter is ^{186}Re .

94. (Currently amended) [[A]] The method according to claim 92, wherein the beta-emitter is ^{90}Y .

95. (Currently amended) [[A]] The method according to claim 89, wherein the compound emitting radiation is a gamma-emitter.

96. (Currently amended) [[A]] The method according to claim 95, wherein the gamma-emitter is ^{131}I .

97. (Currently amended) [[A]] The method according to claim 89, wherein the compound emitting radiation is a beta- and gamma-emitter.

98. (Currently amended) [[A]] The method according to claim 88, wherein the cytotoxic drug is a molecule of bacterial origin.

99. (Currently amended) [[A]] The method according to claim 88, wherein the cytotoxic drug is a molecule of plant origin.

100. (Currently amended) [[A]] The method according to claim 88, wherein the cytotoxic drug is a biological protein.

101. (Currently amended) [[A]] The method according to claim 58[[, 70]] or 72, wherein the antibody or antigen binding portion thereof ~~further~~ comprises a label.

102. (Currently amended) [[A]] The method according to claim 101, wherein the label is selected from the group consisting of a biologically-active enzyme label and a radiolabel.

103. (Currently amended) [[A]] The method according to claim 101, wherein the label is a radiolabel selected from the group consisting of ^{111}In , $^{99\text{m}}\text{Tc}$, $^{99\text{m}}\text{Tc}$, ^{32}P , ^{125}I , and ^{188}Rh .

104. (Currently amended) [[A]] The method according to claim 58[[, 70]] or 72, wherein the antibody or antigen binding portion thereof is effective to initiate an endogenous host immune function.

105. (Currently amended) [[A]] The method according to claim 104, wherein the endogenous host immune function is complement-mediated cellular ~~cytotoxicity~~ cytotoxicity.

106. (Currently amended) [[A]] The method according to claim 104, wherein the endogenous host immune function is antibody-dependent cellular ~~cytotoxicity~~ cytotoxicity.

107. (Currently amended) [[A]] The method according to claim 58[[, 70]] or 72, wherein the antibody or antigen binding portion thereof is in a composition further comprising a pharmaceutically acceptable carrier, excipient, or stabilizer.

108. (Currently amended) The method according to claim 58[[, 70]] or 72, wherein the antibody is administered in conjunction with a second therapeutic modality.

109. (Previously presented) The method according to claim 108, wherein the second therapeutic modality is selected from the group consisting of surgery, radiation, chemotherapy, immunotherapy and hormone replacement.

110. (Previously presented) The method according to claim 109, wherein the hormone replacement comprises treatment with estrogen or an anti-androgen agent.

111. (Previously presented) The method according to claim 110, wherein the anti-androgen agent is an agent which blocks or inhibits the effects of testosterone.

112. (Canceled)

113. (Previously presented) The method according to claim 72, wherein the antibody or antigen binding portion thereof competes for binding to prostate specific membrane antigen (PSMA) with a J415 monoclonal antibody.